MDT

94.36

-0.74%↓

VEEV

291.44

-1.79%↓

A

137.43

+7.91%↑

HQY

90.49

-3.93%↓

PHR.US

22.49

-4.42%↓

MDT

94.36

-0.74%↓

VEEV

291.44

-1.79%↓

A

137.43

+7.91%↑

HQY

90.49

-3.93%↓

PHR.US

22.49

-4.42%↓

MDT

94.36

-0.74%↓

VEEV

291.44

-1.79%↓

A

137.43

+7.91%↑

HQY

90.49

-3.93%↓

PHR.US

22.49

-4.42%↓

MDT

94.36

-0.74%↓

VEEV

291.44

-1.79%↓

A

137.43

+7.91%↑

HQY

90.49

-3.93%↓

PHR.US

22.49

-4.42%↓

MDT

94.36

-0.74%↓

VEEV

291.44

-1.79%↓

A

137.43

+7.91%↑

HQY

90.49

-3.93%↓

PHR.US

22.49

-4.42%↓

Search

Akebia Therapeutics Inc

Abierto

SectorSanidad

2.69

Resumen

Variación precio

24h

Actual

Mínimo

2.68

Máximo

2.73

Métricas clave

By Trading Economics

Ingresos

-5.9M

247K

Ventas

5.1M

62M

Margen de beneficios

0.395

Empleados

181

EBITDA

-6.1M

7.4M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+156.41% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-162M

726M

Apertura anterior

2.69

Cierre anterior

2.69

Noticias sobre sentimiento de mercado

By Acuity

94%

6%

356 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Akebia Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 sept 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30 sept 2025, 23:43 UTC

Acciones populares

Stocks to Watch: GEO Group, Lithium Americas, Nike

30 sept 2025, 23:12 UTC

Ganancias

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30 sept 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30 sept 2025, 22:01 UTC

Adquisiciones, fusiones, absorciones

Lifeway Foods, Danone Agree to Stay Litigation

30 sept 2025, 21:17 UTC

Ganancias

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30 sept 2025, 20:47 UTC

Ganancias

Nike 1Q Sales Rise as Turnaround Progresses

30 sept 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30 sept 2025, 23:45 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30 sept 2025, 23:26 UTC

Adquisiciones, fusiones, absorciones

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30 sept 2025, 23:26 UTC

Adquisiciones, fusiones, absorciones

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30 sept 2025, 23:25 UTC

Adquisiciones, fusiones, absorciones

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30 sept 2025, 23:24 UTC

Adquisiciones, fusiones, absorciones

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30 sept 2025, 23:24 UTC

Adquisiciones, fusiones, absorciones

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30 sept 2025, 22:54 UTC

Charlas de Mercado

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30 sept 2025, 22:38 UTC

Ganancias

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 sept 2025, 22:32 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 sept 2025, 22:32 UTC

Charlas de Mercado

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30 sept 2025, 22:03 UTC

Adquisiciones, fusiones, absorciones

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 sept 2025, 21:32 UTC

Adquisiciones, fusiones, absorciones

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 sept 2025, 21:02 UTC

Ganancias

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 sept 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

30 sept 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

30 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 sept 2025, 20:28 UTC

Ganancias

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30 sept 2025, 20:22 UTC

Ganancias

Nike 1Q North America Revenue $5.02B >NKE

30 sept 2025, 20:22 UTC

Ganancias

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30 sept 2025, 20:22 UTC

Ganancias

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30 sept 2025, 20:22 UTC

Ganancias

Nike 1Q Greater China Revenue $1.51B >NKE

30 sept 2025, 20:19 UTC

Ganancias

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Comparación entre iguales

Cambio de precio

Akebia Therapeutics Inc previsión

Precio Objetivo

By TipRanks

156.41% repunte

Estimación a 12 Meses

Media 7 USD  156.41%

Máximo 8 USD

Mínimo 6 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Akebia Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.345 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

356 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat